Anti-Coagulants - Albania

Albania

In Albania, the revenue in the Anti-Coagulants market is projected to reach US$2.43m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 7.75%, resulting in a market volume of US$3.53m by 2029.
When compared globally, United States is predicted to generate the highest revenue, with US$16,740.00m in 2024.
Albania's anti-coagulant market is experiencing a surge due to an aging population and an increase in cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Albania has been on a steady rise in recent years, driven by various factors such as an aging population, increasing prevalence of cardiovascular diseases, and advancements in medical technology.

Customer preferences: Patients in Albania are increasingly opting for oral anticoagulants over traditional injectable anticoagulants due to their convenience and ease of use. Additionally, there is a growing preference for newer anticoagulants that have fewer side effects and do not require frequent monitoring.

Trends in the market: The Anti-Coagulants market in Albania is expected to continue its growth trajectory in the coming years, driven by increasing healthcare expenditure and a growing awareness of the benefits of anticoagulant therapy. The market is also likely to see a shift towards the use of newer oral anticoagulants as they become more widely available and affordable.

Local special circumstances: Despite the growing demand for anticoagulants in Albania, the market is still relatively underdeveloped compared to other European countries. This is due to various factors such as limited access to healthcare services, a lack of awareness among the general population, and a shortage of skilled healthcare professionals.

Underlying macroeconomic factors: The Albanian economy has been steadily growing in recent years, driven by increased investment and a growing tourism industry. This has led to an increase in disposable income and a rise in healthcare expenditure, which is expected to further boost the Anti-Coagulants market in the country. However, the market is also likely to face challenges such as a shortage of skilled healthcare professionals and limited access to healthcare services in rural areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.